S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795–806. https://pubmed.ncbi.nlm.nih.gov/28068222/
8297
Ummarino S, Mozzon M, Zamporlini F, et al. Simultaneous quantitation of nicotinamide riboside, nicotinamide mononucleotide and nicotinamide adenine dinucleotide in milk by a novel enzyme-coupled assay. Food Chem. 2017;221:161–8. https://pubmed.ncbi.nlm.nih.gov/27979136/
8298
Turner J, Licollari A, Mihalcea E, Tan A. Safety evaluation for Restorin® NMN, a NAD+ precursor. Front Pharmacol. 2021;12:749727. https://pubmed.ncbi.nlm.nih.gov/34867355/
8299
You Y, Gao Y, Wang H, et al. Subacute toxicity study of nicotinamide mononucleotide via oral administration. Front Pharmacol. 2020;11:604404. https://pubmed.ncbi.nlm.nih.gov/33384603/
8300
Poddar SK, Sifat AE, Haque S, Nahid NA, Chowdhury S, Mehedi I. Nicotinamide mononucleotide: exploration of diverse therapeutic applications of a potential molecule. Biomolecules. 2019;9(1):34. https://pubmed.ncbi.nlm.nih.gov/30669679/
8301
NDI 1259-B-Nicotinamide Mononucleotide (NMN) from Inner Mongolia Kingdomway Pharmaceutical Limited. U.S. Food and Drug Administration. https://www.regulations.gov/document/FDA-2022-S-0023–0051. Published November 8, 2022. Accessed February 25, 2023.; https://www.regulations.gov/document/FDA-2022-S-0023-0051
8302
Ramsey KM, Mills KF, Satoh A, Imai SI. Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell. 2008;7(1):78–88. https://pubmed.ncbi.nlm.nih.gov/18005249/
8303
Li C, Wu LE. Risks and rewards of targeting NAD+ homeostasis in the brain. Mech Ageing Dev. 2021;198:111545. https://pubmed.ncbi.nlm.nih.gov/34302821/
8304
Braidy N, Liu Y. NAD+ therapy in age-related degenerative disorders: a benefit/risk analysis. Exp Gerontol. 2020;132:110831. https://pubmed.ncbi.nlm.nih.gov/31917996/
8305
Cohen MS. Axon degeneration: too much NMN is actually bad? Curr Biol. 2017;27(8):R310–2. https://pubmed.ncbi.nlm.nih.gov/28441566/
8306
Williams PA, Harder JM, John SWM. Glaucoma as a metabolic optic neuropathy: making the case for nicotinamide treatment in glaucoma. J Glaucoma. 2017;26(12):1161–8. https://pubmed.ncbi.nlm.nih.gov/28858158/
8307
Di Stefano M, Nascimento-Ferreira I, Orsomando G, et al. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration. Cell Death Differ. 2015;22(5):731–42. https://pubmed.ncbi.nlm.nih.gov/25323584/
8308
Di Stefano M, Loreto A, Orsomando G, et al. NMN deamidase delays Wallerian degeneration and rescues axonal defects caused by NMNAT2 deficiency in vivo. Curr Biol. 2017;27(6):784–94. https://pubmed.ncbi.nlm.nih.gov/28262487/
8309
Cohen MS. Axon degeneration: too much NMN is actually bad? Curr Biol. 2017;27(8):R310–2. https://pubmed.ncbi.nlm.nih.gov/28441566/
8310
Quantitative analysis of twenty-two NMN consumer products. ChromaDex. https://s23.q4cdn.com/937095816/files/doc_downloads/2021/Quantitative-Analysis-of-22-NMN-Consumer-Products-Oct-2021.pdf. Published October 20, 2021. Accessed January 10, 2023.; https://investors.chromadex.com/investor-resources/Market-Surveillance/default.aspx
8311
Cooperman T. NAD booster supplements review (NAD+/NADH, nicotinamide riboside, and NMN). ConsumerLab.com. https://www.consumerlab.com/reviews/nmn-nadh-nicotinamide-riboside/nmn-nadh-nicotinamide-riboside/#related-clinical-updates. Published November 2, 2021. Updated November 14, 2022. Accessed January 11, 2023.; https://www.consumerlab.com/reviews/nmn-nadh-nicotinamide-riboside/nmn-nadh-nicotinamide-riboside/#related-clinical-updates
8312
Correll WA, Viswanathan S. Warning letter: ChromaDex MARCS-CMS 607692–11/17/2020. U.S. Food and Drug Administration. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chromadex-607692–11172020. Updated December 1, 2020. Accessed January 10, 2023.; https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chromadex-607692-11172020
8313
BBB National Programs. ChromaDex, Inc. Discontinues advertising claims for Tru Niagen dietary supplement following national advertising division challenge. Cision PR Newswire. https://www.prnewswire.com/news-releases/chromadex-inc-discontinues-advertising-claims-for-tru-niagen-dietary-supplement-following-national-advertising-division-challenge-301392733.html. Published October 5, 2021. Accessed January 10, 2023.; https://www.prnewswire.com/news-releases/chromadex-inc-discontinues-advertising-claims-for-tru-niagen-dietary-supplement-following-national-advertising-division-challenge-301392733.html
8314
Segall PE, Timiras PS. Patho-physiologic findings after chronic tryptophan deficiency in rats: a model for delayed growth and aging. Mech Ageing Dev. 1976;5(2):109–24. https://pubmed.ncbi.nlm.nih.gov/933560/
8315
De Marte ML, Enesco HE. Influence of low tryptophan diet on survival and organ growth in mice. Mech Ageing Dev. 1986;36(2):161–71. https://pubmed.ncbi.nlm.nih.gov/3784629/
8316
Conlon N, Ford D. A systems-approach to NAD+ restoration. Biochem Pharmacol. 2022;198:114946. https://pubmed.ncbi.nlm.nih.gov/35134387/
8317
Kimura N, Fukuwatari T, Sasaki R, Shibata K. Comparison of metabolic fates of nicotinamide, NAD+ and NADH administered orally and intraperitoneally; characterization of oral NADH. J Nutr Sci Vitaminol. 2006;52(2):142–8. https://pubmed.ncbi.nlm.nih.gov/16802695/
8318
Zapata-Pérez R, Tammaro A, Schomakers BV, et al. Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice. FASEB J. 2021;35(4):e21456. https://pubmed.ncbi.nlm.nih.gov/33724555/
8319
Giroud-Gerbetant J, Joffraud M, Giner MP, et al. A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor. Mol Metab. 2019;30:192–202. https://pubmed.ncbi.nlm.nih.gov/31767171/
8320
Chini CCS, Peclat TR, Gomez LS, et al. Dihydronicotinamide riboside is a potent NAD+ precursor promoting a pro-inflammatory phenotype in macrophages. Front Immunol. 2022;13:840246. https://pubmed.ncbi.nlm.nih.gov/35281060/
8321
Sonavane M, Hayat F, Makarov M, Migaud ME, Gassman NR. Dihydronicotinamide riboside promotes cell-specific cytotoxicity by tipping the balance between metabolic regulation and oxidative stress. PLoS One. 2020;15(11):e0242174. https://pubmed.ncbi.nlm.nih.gov/33166357/
8322
Chini CCS, Peclat TR, Gomez LS, et al. Dihydronicotinamide riboside is a potent NAD+ precursor promoting a pro-inflammatory phenotype in macrophages. Front Immunol. 2022;13:840246. https://pubmed.ncbi.nlm.nih.gov/35281060/
8323
Poljsak B, Kovac V, Milisav I. Healthy lifestyle recommendations: do the beneficial effects originate from NAD+ amount at the cellular level? Oxid Med Cell Longev. 2020;2020:8819627. https://pubmed.ncbi.nlm.nih.gov/33414897/
8324
Oakey LA, Fletcher RS, Elhassan YS, et al. Metabolic tracing reveals novel adaptations to skeletal muscle cell energy production pathways in response to NAD+ depletion. Wellcome Open Res. 2018;3:147. https://pubmed.ncbi.nlm.nih.gov/30607371/
8325
Braidy N, Liu Y. NAD+ therapy in age-related degenerative disorders: a benefit/risk analysis. Exp Gerontol. 2020;132:110831. https://pubmed.ncbi.nlm.nih.gov/31917996/
8326
Palmer RD, Vaccarezza M. Nicotinamide adenine dinucleotide and the sirtuins caution: pro-cancer functions. Aging Med (Milton). 2021;4(4):337–44. https://pubmed.ncbi.nlm.nih.gov/34964015/
8327
Poljsak B, Kovac V, Milisav I. Healthy lifestyle recommendations: do the beneficial effects originate from NAD+ amount at the cellular level? Oxid Med Cell Longev. 2020;2020:8819627. https://pubmed.ncbi.nlm.nih.gov/33414897/
8328
Liu Y, Clement J, Grant R, Sachdev P, Braidy N. Quantitation of NAD+: why do we need to measure it?
